(10) Investments by the United States in af-
fordable, appropriate health technologies, such as 
medical devices for maternal, newborn, and child 
care; new vaccines; new vaccine technologies and de-
livery tools; safe injection devices; diagnostic tests 
for infectious diseases; new tools for water, sanita-
tion, and nutrition; multipurpose prevention tech-
nologies; information systems and mobile health and 
information systems; and innovative disease preven-
tion strategies— 
(A) reduce the risk of disease transmission; 
(B) accelerate access to life-saving global 
health interventions for the world’s poor; 
(C) reduce the burden on local health sys-
tems; and 
(D) have been found by the United States 
Government and WHO to result in significant 
cost savings for development assistance funds. 
(11) Where markets fail, public-private partner-
ships are an effective way to develop, introduce and 
scale up new health technologies. Product develop-
ment partnerships (PDPs) are one model of public 
private partnership that is successfully accelerating 
research to benefit the developing world. PDPs are 
non-profit, nongovernmental entities that work to 
VerDate Mar 15 2010 
02:16 Apr 19, 2013
Jkt 029200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H1515.IH
H1515
tjames on DSK6SPTVN1PROD with BILLS
accelerate the development of new tools to fight dis-
eases in resource-poor settings. Typically, PDPs 
manage resources and partnerships from across pub-
lic, private, and philanthropic sectors to drive the 
development of a full pipeline of potential new prod-
ucts that could save and improve lives in the devel-
oping world. USAID has played a significant role in 
advancing the PDP model through its financial sup-
port. Over the past decade, the achievements of 
PDPs have become increasingly successful at ad-
vancing new products through the development pipe-
line towards registration, product introduction, and 
use. 
(12) USAID supports research and introduction 
activities along a research-to-use continuum includ-
ing— 
(A) evidence reviews and health assess-
ments in developing countries; and 
(B) the development, testing, adaptation, 
and introduction of appropriate products and 
interventions within the context of strength-
ening health systems. 
(13) A Center for Accelerating Innovation and 
Impact has been established at USAID to address 
technical, supply and policy barriers in the develop-
VerDate Mar 15 2010 
02:16 Apr 19, 2013
Jkt 029200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H1515.IH
H1515
tjames on DSK6SPTVN1PROD with BILLS
ment, introduction and scale-up of new products and 
technologies for global health. For diseases and con-
ditions where market forces have proven insufficient 
to generate and rapidly deliver new technologies, the 
Center promotes and reinforces solutions to over-
come obstacles such as regulatory inefficiencies in 
developing countries, limited user demand, gaps in 
market data and supply chain hurdles. The Center 
also catalyzes partnerships with the public and pri-
vate sectors to develop and rapidly deploy new prod-
ucts. 
(14) Through a cooperative agreement, known 
as the Health Technologies program, USAID sup-
ports the development of technologies that— 
(A) maximize the limited resources avail-
able for global health; and 
(B) ensure that products and medicines 
developed for use in low-resource settings reach 
the people that need such products and medi-
cines. 
Through the Health Technologies program, 85 tech-
nologies have been invented, designed, developed or 
co-developed and more than 100 private-sector col-
laborators have been involved in the Health Tech-
nologies program, matching USAID dollars at least 
VerDate Mar 15 2010 
00:05 Apr 20, 2013
Jkt 029200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H1515.IH
H1515
tjames on DSK6SPTVN1PROD with BILLS
two to one. Over its 25-year history, more than 95 
private-sector collaborators have been involved in the 
Health Technologies program, matching USAID dol-
lars two to one. 
(15) USAID’s research and development is 
complementary to the work of other agencies. 
SEC. 3. PURPOSES. 
The purpose of this Act is to acknowledge USAID’s 
role in product development, introduction and scale-up of 
new global health tools and authorize USAID’s Health 
Technologies program, in effect as of the date of the en-
actment of this Act, under which the United States Agen-
cy for International Development supports the develop-
ment of technologies for global health to— 
(1) improve global health; 
(2) reduce maternal, newborn, and child mor-
tality rates; 
(3) reverse the incidence of HIV/AIDS, malaria, 
tuberculosis, and other infectious diseases; 
(4) reduce the burden of chronic diseases; 
(5) overcome technical, supply and policy hur-
dles to product introduction and scale-up; and 
(6) support research and development that is 
consistent with a global development strategy and 
other related strategies developed by USAID. 
VerDate Mar 15 2010 
00:05 Apr 20, 2013
Jkt 029200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H1515.IH
H1515
tjames on DSK6SPTVN1PROD with BILLS
SEC. 4. CODIFICATION OF HEALTH TECHNOLOGIES PRO-
GRAM. 
Section 107 of the Foreign Assistance Act of 1961 
(22 U.S.C. 2151e) is amended by adding at the end the 
following: 
‘‘(c) HEALTH TECHNOLOGIES PROGRAM.—(1) There 
is established in the United States Agency for Inter-
national Development (USAID) a health technologies pro-
gram (referred to in this subsection as the ‘program’). 
‘‘(2) The program shall develop, advance, and intro-
duce affordable, available, and appropriate and primarily 
late-stage technologies specifically designed to— 
‘‘(A) improve the health and nutrition of popu-
lations in developing countries; 
‘‘(B) reduce maternal, newborn, and child mor-
tality in such countries; and 
‘‘(C) improve the diagnosis, prevention, and re-
duction of disease, especially HIV/AIDS, malaria, 
tuberculosis, and other infectious diseases, in such 
countries. 
‘‘(3) The program shall be carried out under a coop-
erative agreement between USAID and one or more insti-
tutions with a successful record of— 
‘‘(A) advancing the technologies described in 
paragraph (2); and 
VerDate Mar 15 2010 
00:05 Apr 20, 2013
Jkt 029200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H1515.IH
H1515
tjames on DSK6SPTVN1PROD with BILLS
SEC. 5. REPORT ON RESEARCH AND DEVELOPMENT AC-
TIVITIES AT USAID. 
(a) IN GENERAL.—The Administrator of the United 
States Agency for International Development (referred to 
in this section as ‘‘USAID’’) shall submit to Congress an 
annual report on research and development activities at 
USAID. 
(b) MATTERS TO BE INCLUDED.—The report re-
quired by subsection (b) shall describe— 
(1) updates on the implementation of its strat-
egy for using research funds to stimulate the devel-
opment and introduction of products in each of its 
global health and development programs; 
(2) USAID’s collaborations and coordination 
with other Federal departments and agencies in sup-
port of translational and applied global health re-
search and development; 
(3) its investments for the fiscal year in science, 
technology, and innovation; 
(4) how these technologies and research prod-
ucts complement the work being done by other Fed-
eral departments and agencies, if applicable; and 
(5) technologies and research products that 
have been introduced into field trials or use. 
(c) CONSULTATION.—The Administrator of USAID 
shall consult on an annual basis with the heads of other 
VerDate Mar 15 2010 
02:16 Apr 19, 2013
Jkt 029200
PO 00000
Frm 00014
Fmt 6652
Sfmt 6201
E:\BILLS\H1515.IH
H1515
tjames on DSK6SPTVN1PROD with BILLS
Federal departments and agencies to improve alignment 
of USAID’s health-related research strategy with other 
similar agency strategies, with the intent of working to-
wards a whole-of-government strategy for global health re-
search and development. 
Æ 
VerDate Mar 15 2010 
02:16 Apr 19, 2013
Jkt 029200
PO 00000
Frm 00015
Fmt 6652
Sfmt 6301
E:\BILLS\H1515.IH
H1515
tjames on DSK6SPTVN1PROD with BILLS